Document 2018
 DOCN  M94A2018
 TI    The dilemma of developing a vaccine against HIV.
 DT    9412
 AU    Bolognesi DP; Duke University Medical Center, Durham, NC.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):4 (abstract no. PS4). Unique
       Identifier : AIDSLINE ICA10/94370557
 AB    Despite an unprecedented research and development effort that has been
       ongoing since the mid 1980's the quest for a vaccine against HIV has and
       continues to experience a pattern of unsteady progress. Animal model
       studies have not produced uniform guiding principles but rather a
       complex and often confusing picture. Frustrated, vaccine developers have
       turned to man as the experimental model but here too unanticipated
       obstacles have stymied progress. With over a dozen vaccine candidates in
       clinical trials including two in Phase II studies and an infrastructure
       being prepared to accept vaccines for large scale efficacy trials, the
       HIV vaccine field is at a crossroads, with forward movement difficult in
       the absence of clear correlates of immunity. At the same time several
       new developments stemming from studies of HIV pathogenesis may help
       point the way toward a better understanding of correlates of protection
       and with several promising vaccine strategies under development, the
       outlook for eventual success remains plausible. These and other issues
       related to HIV vaccines will be discussed.
 DE    Acquired Immunodeficiency Syndrome/PREVENTION & CONTROL  AIDS
       Vaccines/*ISOLATION & PURIF  Human  HIV/*IMMUNOLOGY  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).